Societe Generale’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Societe Generale’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$1.16M	Buy	+7,940	New	+$1.13M	0.01%	1207

Other funds holding TARO

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Societe Generale's TARO Position: Q2 2016 in Review

Societe Generale opened a new position in Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2016: 7,940 shares worth $1.16M. The stake represents 0.01% of the portfolio and ranks #1207 among its holdings.

159 funds tracked by Wall St. Rank hold TARO as of Q2 2016.

Societe Generale held 7,940 shares of Taro Pharmaceutical Industries Ltd. worth $1.16M as of Q2 2016.
Taro Pharmaceutical Industries Ltd. was a new Societe Generale position in Q2 2016.
Taro Pharmaceutical Industries Ltd. made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1207 holding.
159 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.